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1 ABSTRACT 
Introduction 
In South Africa, in 2007 there were 139 new cases of anal cancer. This 
malignancy shows a female predominance and is associated with several risk 
factors including smoking and infection with Human Immunodeficiency Virus and 
Human Papilloma Virus. The standard of care for the treatment of localised anal 
cancer is concurrent chemo-radiation.       
The purpose of this retrospective study was to describe the patient characteristics 
and the treatment toxicity of chemo-radiation in patients with localized squamous 
cell anal cancer. A further aim was to describe the treatment outcomes. 
Materials and Methods 
A total of 64 patients with anal carcinoma, who presented to the department of 
radiation oncology at Charlotte Maxeke Johannesburg Academic Hospital between 
2006 and 2012, were included in the study.  
Only squamous cell carcinoma histological subtypes of anal carcinoma qualified 
for inclusion in the study. Patients with metastatic anal carcinoma were excluded 
from the study. Data about patient and tumour characteristics, treatment toxicities 
and treatment response were captured in a proforma sheet.  
Once data collection was complete, statistical analysis using the SAS software 
package was carried out. 
Results 
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The median age at first consultation was 48 years. Sixty-seven per cent of the 
study group was female. Sixty-eight per cent of patients presented with advanced 
tumours (T3/T4) and 60% of the patients had node positive disease. Fifty per cent 
of patients were Human Immunodeficiency Virus positive with a median cluster of 
differentiation 4 (CD4) cell count of 250 cells/mm3.   
The predominant adverse effects were skin toxicity in 81% of patients and pain in 
75% of patients. 
Thirty-eight per cent of patients who followed-up after treatment completion 
experienced a tumour recurrence at a median duration of 303 days after 
treatment. The progression free survival estimates at 12 months were 85% and at 
24 months were 46%.  
Conclusion 
The patient population presenting to Charlotte Maxeke Johannesburg Academic 
Hospital radiation oncology department was predominantly comprised of middle 
aged females with advanced stages of anal carcinoma. Approximately half of 
these patients were Human Immunodeficiency Virus positive.  
Skin toxicity and pain were the commonest adverse effects observed.  
There was a high recurrence rate noted, likely due to the fact that most patients 
presented with advanced disease.  
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5 INTRODUCTION 
5.1 BURDEN OF DISEASE 
In South-Africa in 2007, there were 62 new cases of anal cancer in men, 
constituting a lifetime risk of 1/2479 people and there were 77 new cases of anal 
cancer in women, constituting a lifetime risk of 1/2389 people.1 
The majority of anal cancers are squamous cell carcinomas (85-90%), while the 
remainder are adenocarcinomas or other rare variants.2 
5.2 RISK FACTORS 
Risk factors associated with anal cancer are infection with HPV -particularly 
subtypes 16 and 18, female gender, sexual promiscuity, cigarette smoking, 
sexually transmitted infections, genital warts, receptive anal intercourse and 
infection with HIV- especially if the CD4 count is <200 cells/mm3. The risk of 
developing anal cancer in men with HIV is reported to be 37.9 times higher than in 
non-HIV infected males, and 6.8 times higher in HIV infected women, versus HIV 
negative females.3,4   
5.3 NATURAL HISTORY 
Anal cancer is a slowly progressing disease that begins as a superficial mass. It is 
predominantly a loco-regional disease, although distant metastasis occurs in 20% 
of cases.5 
Although anal cancer causes early symptoms and is easily accessible to clinical 
examination, patients often present with advanced disease.6 
5.4 STAGING 
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Anal cancer is staged according to the AJCC 7th edition TNM staging criteria 
(appendix 1).  
5.5 PROGNOSIS 
Factors that have been identified to portend for a poor prognosis in anal cancer 
are a tumour diameter >5cm, node positive disease and male gender. The 
response of the tumour to chemo-radiotherapy has also been shown to have 
prognostic significance.7,8 
Despite the frequent late presentation of anal cancer, after treatment with 
combined concomitant chemo-radiation the progression free and overall survival 
rates are high. The progression free survival rate at three years, for advanced anal 
cancers is 40-68%.17 The five year overall survival is 84% and the 8 year overall 
survival is 77%. The colostomy free survival at 5 and 8 years is 71% and 67% 
respectively.9  
5.6 MANAGEMENT 
The management of anal cancer has evolved greatly over the years. Treatment 
has changed from abdomino-perineal resection, which was considered the 
standard of care before 1980, to conservative therapy with concurrent chemo-
radiation.13  In 1973 Nigro et al. introduced a schedule of 5-fluorouracil (5FU) and 
mitomycin c chemotherapy, combined with radiotherapy to treat anal cancer. The 
use of chemo-radiotherapy has since been adopted as the standard of care and is 
considered “a model for organ conservative treatment”.8 
There is concern over giving concurrent chemo-radiotherapy in HIV positive 
patients as there have been reports of worse toxicities and poorer clinical 
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outcomes. The severe toxicity reactions may necessitate treatment breaks and 
chemotherapy or radiotherapy dose adjustments.3,10 
Studies have shown conflicting results of treatment of anal carcinoma in HIV 
positive patients with some showing equivalent outcomes to non-HIV infected 
patients and others showing worse toxicity and outcomes.3 
The work-flow pertaining to anal carcinoma patients at CMJAH is as follows- 
On the initial visit, a history and physical examination are carried out. All relevant 
investigations are performed, such as blood tests, staging tests and a metastatic 
work-up. Following this, the patient is booked for a planning CT scan. After the CT 
scan has been done, fields are placed and treatment is prescribed, based on the 
results of the history, examination and investigations documented in the patients 
file.  
Although the departmental protocols (see below) are to prescribe concurrent 
chemo-radiotherapy with mitomycin c and 5FU, modifications are required in 
certain cases. For example, patients with HIV and a low white cell count, or a low 
CD4 count may be prescribed cisplatin instead of mitomycin c, or may be 
prescribed radiotherapy only.  
Once field placement and the prescription are complete, the patient is then 
contacted with a date for verification and treatment initiation. 
At CMJAH the population of patients with anal cancer consists of both HIV 
negative and HIV infected patients. The CMJAH protocol for treating anal 
carcinoma with concurrent chemo-radiation is as follows- 
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Chemotherapy consists of 5FU at 400mg/m2 intravenously as a bolus on days 1-4 
and 22-25 of radiation, as well as mitomycin c 10mg/m2 intravenous bolus 
injection on day 1 of radiation. 
Radiation therapy consists of three phases. The phase 1 dose is 30Gy in 15 
fractions, at 2Gy per fraction. This encompasses the primary tumour, the anus and 
the regional lymph nodes. The superior field border is the interspace between 
L5/S1 vertebrae, the inferior field border is the tumour and a 3cm margin, and 
laterally the field borders are placed on the outer acetabulum, so as to include the 
pelvic and inguinal lymph nodes.  
Phase 2 involves treating the tumour, the anus and any remaining clinically 
involved lymph nodes with an additional 20Gy in 10 fractions to a total of 50Gy, at 
2Gy per fraction. This field may have the same field borders as Phase 1 if there 
were clinically positive lymph nodes. If the inguinal lymph nodes were negative for 
metastatic disease, the lateral field borders may be moved medially, to give a 2cm 
margin on the pelvic brim.  
This is then followed by phase 3, a tumour boost of 6-10Gy, which treats only the 
residual tumour with a 3cm margin. If there is no residual disease after 50Gy 
(phases 1 and 2), then the boost may be omitted.  
There is no scheduled gap in the treatment. If severe toxicity occurs, splits in 
treatment are introduced at the discretion of the treating oncologist. Thus from 
start to finish, treatment should take between 5 to 6 weeks, or 35 to 42 days in 
total, provided no split in treatment is required. 
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A gap, or a split, increases the overall treatment time and thus may predispose to 
worse outcomes, as seen in a trial by Graf R, et al.11 They observed that an overall 
treatment time in excess of 41 days predisposed to reduced local control in anal 
cancer. Thus the length of the treatment gap is significant. Oehler C et al noted 
impaired cancer specific survival with a split of seven days or longer.12 
5.7 AIM  
The aim of the study was to describe the patient characteristics, the acute 
treatment toxicities and the progression free and overall survival outcomes of the 
population of patients with squamous cell anal cancer who were accepted for 
radical treatment with concurrent chemo-radiotherapy at CMJAH from 2006-2012. 
Page 17 of 72 
6 LITERATURE REVIEW 
6.1 PATIENTS CHARACTERISTICS  
6.1.1 DEMOGRAPHICS  
Age and Gender- in a review of the SEER programme data collected between 
1973-2000, Johnson et al found that between 1973-1979 the incidence of anal 
carcinoma in women was higher, but between 1994-2000, men had a higher 
incidence. In both genders, the rate of anal carcinoma was highest in patients 65 
years and older. The authors attributed the change in the disease gender 
distribution to the fact that in the USA, HIV rates had increased predominantly in 
men during that same time period.4 
Ajani et al analysed the prospective database of the intergroup 98-11 trial, looking 
for prognostic variables in anal carcinoma. In addition to other prognostic 
variables, they found male gender to be a poor prognostic factor. Anal cancer was 
commoner in females, and females comprised 69% of the sample group, but they 
had better outcomes than their male counterparts.7 
Gerard et al did a prospective trial to evaluate the long term outcomes of high 
dose radiotherapy and concomitant fluorouracil. They included 95 HIV negative 
patients in their evaluation. The median age of patients was 63 year of age. 
Ninety-one per cent of their study population was female.9  
A trial looking at concurrent chemo-radiation for anal carcinoma, in HIV positive 
patients on HAART, found that the median age of patients at diagnosis was 45 
years.3 In another trial which included HIV infected patients with anal carcinoma, 
the median age of patients at presentation was 38 years.14   
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Thus the literature review of anal carcinoma showed a female predominance, with 
a younger median age of presentation in HIV positive patients. HIV infected 
individuals presented with the disease approximately two decades earlier. 
6.1.2 HIV  STATUS  
  
A trial conducted by Place et al at the University of Texas, looked at the outcomes 
of a cohort of 23 HIV positive patients with anal carcinoma treated with chemo-
radiation. Fourteen of the patients in the group had invasive anal squamous 
carcinoma, and the remainder had in situ disease. The data was collected 
retrospectively from records of patients treated between 1980 and 1999.  
Those patients treated from 1998 and onwards were all commenced on 
antiretroviral therapy prior to initiating treatment. Thus the majority of the patients 
in this study cohort were not on antiretroviral therapy when they were treated. The 
average CD4 count of patients was 222 cells/mm3 for those patients with invasive 
disease, and 200 cells/mm3 for those with in situ disease.  
The authors found that a low CD4 count at diagnosis, without the use of 
antiretroviral therapy, predicated for a poor prognosis. The one and five year 
mortality rates were 40% and 80% respectively. They also reported that the 
patients with AIDS succumbed to complications related to AIDS before 
succumbing to anal cancer, experienced worse toxicity from treatment and had 
poorer outcomes. Of the 10 patients who demised, 8 still had persistent local 
disease but they did not have distant metastases. The authors hypothesised that if 
antiretroviral therapy had been initiated in all patients prior to starting treatment, 
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there may have been reduced treatment toxicity and improved therapeutic 
outcomes.10 
Cleator et al reported that in their group of 12 HIV positive patients, the median 
CD4 count was 209 cells/mm3 at diagnosis and 9/12 patients were on ARV 
therapy at presentation. The 9 of 12 patients had early disease (T1 and T2) and 
only one patient had node positive disease. Eleven patients were available for 
follow-up. At the end of treatment, 9 patients had a complete remission, 1 patient 
had a partial response but was salvaged with abdomino-perineal resection and 1 
patient had disease progression on treatment and died of anal cancer. After a 
median follow-up at 4.8 years, 4 patients had demised. Two died from the anal 
cancer, 1 from opportunistic infection and 1 died from treatment complications.15       
In summary, the literature showed that HIV positive patients who were on 
antiretroviral therapy had less treatment toxicity and better outcomes than those 
not on ARVs. In addition, although patients had comorbid HIV, those who 
presented with early disease had favourable outcomes. 
6.1.3 TUMOUR CHARACTERISTICS  
 
The presenting tumour stage for the 682 patients in the RTOG-98-11 trial included 
27% advanced stage tumours, 5cm or more in size (T3/T4), and 26% had clinically 
involved lymph nodes.7 
In the trial by Gerard et al, which included 95 patients, 63% of the study population 
had tumours that were 4cm or larger in maximal diameter, and only 19% had 
tumours smaller than 4cm with no metastatic nodal involvement.9 
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Thus it appears that patients presented with a predominance of advanced stage 
anal carcinoma lesions. 
6.2 TOXICITIES  
In a trial looking at outcomes of combined modality treatment for HIV infected 
patients with squamous cell anal carcinoma, by Edelman et al, the main toxicities 
experienced during treatment were skin and haematological toxicity, in 8 and 9 out 
of 17 patients respectively. Their treatment protocol did not include a planned split, 
and the authors did not report on the frequency of unplanned splits due to toxicity, 
that may have occurred throughout the treatment course.14  
A similar trial by Cleator et al, showed skin toxicity to be the most common (92%), 
followed by GIT toxicity –diarrhoea (83%) and haematological toxicity (50%).15 
A trial by Tanum et al evaluated toxicity and outcomes of treatment in anal 
carcinoma treated with chemo-radiotherapy. One hundred and seventeen patients 
were included in this trial. All patients experienced toxicity but there were no 
treatment related deaths. The commonest toxicities were dermatitis/mucositis, 
fatigue and diarrhoea. Forty nine per cent of patients required a split course of 
treatment due to side effects of treatment.16  
Thus, the commonest treatment toxicities reported in the literature were dermatitis, 
diarrhoea and haematological toxicity.    
6.3 OUTCOMES 
 
Ajani et al found that patients with a tumour diameter >5cm, and those with node 
positive disease had adverse prognostic outcomes, with poorer five year disease 
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free and overall survival outcomes. The combination of a tumour more than 5cm in 
size and node positivity had the worst disease free survival- only 30% were 
disease free at 3 years, compared with 74% of the best group, that is, those with 
tumours<5cm and node negative disease. Four year overall survival in the node 
positive and tumour>5cm group was 48%, compared with 81% for the best 
prognostic factor group.7    
A systematic review of multiple trials of chemo-radiation in anal carcinoma, by Lim 
et al showed a 3 year disease free survival of 40-68% in T3 and T4 cancers. The 5 
year overall survival rates in the non-randomised studies included in this trial 
ranged between 67-91%.17 
In a CALGB trial by Meropol et al, using initial induction chemotherapy with 5-FU 
and cisplatin, followed by concurrent chemo-radiation with mitomycin c and 5-FU, 
the 48 month disease free survival rates were 61%. The 48 month overall survival 
rates were 68%. Patients included in the trial had anal cancer stage T3/T4 and or 
bulky N2/N3 disease.19 
Thus TNM stage is an important prognostic factor, with advanced stages being 
associated with inferior outcomes. 
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7 METHODS 
This was a retrospective study, which included data collected from the files of 64 
patients with anal carcinoma, who were accepted for radical chemo-radiation at 
CMJAH radiation oncology department between 2006 and 2012. 
After obtaining ethics clearance from the WITS Human Research Ethics 
Committee (appendix 6 and 7), the hospital CEO (appendix 8), and the post-
graduate committee (appendix 9) data was collected from patient files. The data 
was collected using a proforma (appendix 2).  
Inclusion criteria were as follows, patients were required to have localized disease 
of the squamous carcinoma histological subtype only. 
Data collection centred around gathering information about patient characteristics 
such as age, gender, HIV status, performance status and risk factors for anal 
carcinoma. Tumour characteristics relating to the TNM stage were also captured. 
Treatment related toxicities were graded where possible, grouped into categories 
and captured for analysis. In cases where patients had presented for post-
treatment follow up visits, information relating to outcomes was also collected. 
Statistical analysis of gathered data was conducted. 
The aim of the study was to describe the local South African patient population 
with anal carcinoma, the treatment they had received, the toxicities they 
experienced whilst on chemo-radiation and to describe the treatment outcomes. A 
further aim was to then compare the local data with international data on anal 
carcinoma in order to assess comparability of the presenting population, tumour 
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stage at presentation, therapeutic regimens and tolerability as well as treatment 
outcomes. 
7.1 STATISTICAL METHODS 
Data analysis was carried out using the software package SAS (version 9.3). 
The chi-squared test was used to assess the relationships between categorical 
variables.  Fisher’s exact test was used for 2 x 2 tables or where the requirements 
for the chi-squared test could not be met. The strength of the associations was 
measured by Cramer’s V and the phi coefficient respectively.   
The relationship between continuous and categorical variables was assessed by 
the t-test (or ANOVA for more than two categories). Where the data did not meet 
the assumptions of these tests, a non-parametric alternative, the Wilcoxon rank 
sum test (or the Kruskal-Wallis test for more than two categories) was used. The 
strength of the associations was measured by the Cohen’s d for parametric tests 
and the r-value for the non-parametric tests.  
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8 RESULTS 
8.1 PATIENT CHARACTERISTICS  
Patients with histological subtypes other than squamous cell carcinoma were 
excluded from the trial. Patients” who presented with metastatic disease or had 
disease progression requiring a change to a palliative regimen while awaiting 
treatment, were also excluded from the trial.  
8.1.1 DEMOGRAPHICS  
The mean age at first consultation was 48 years, with no significant 
difference between the mean ages of men (48) and women (49). The 
distribution of age is shown below. 
 
 
Figure 1: Age at first consultation 
Gender: Sixty-seven per cent of the study group was female. 
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8.1.2 GENERAL CHARACTERISTICS  
Performance status:  
This was measured using the ECOG scale (appendix 3). Fifty per cent of patients 
were ECOG1 at presentation, 27% were ECOG2, 9% ECOG3, 8% ECOG0, and 
the remainder did not have a recorded performance status. 
The distribution of the performance status is shown in the graph below. 
 
Figure 2: Performance status pre-treatment 
Weight and Height at Presentation: 
It was not possible to do an analysis of these variables as they were frequently not 
recorded. 
Colostomy Insertion:  
Sixty-eight per cent of patients had a colostomy inserted. The majority (95%) were 
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regarding anal sphincter preservation rates following treatment completion. This 
was due to insufficient data recorded on follow-up detailing whether the 
colostomies had been reversed and what the anal sphincter tone was on per rectal 
examination following completion of chemo-radiation treatment. 
8.1.3 HIV  STATUS  
Fifty per cent of the patients were HIV-positive, while 28% were HIV-negative. 
Data regarding HIV status was missing in the remaining 22% of patients. 
In the HIV-positive patients: 
The median CD4 count was 250 cells/mm3. Thirty-eight per cent of the patients 
had CD4 counts <=200 cells/mm3, while 56% had CD4 counts above 200 
cells/mm3. The distribution of CD4 counts is shown in the graph below. 
 
Figure 3: CD4 count pre-treatment 
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ARV usage: 
Seventy-eight per cent of the patients were on ARV’s at their first consultation in 
the department. 
Of the 7 patients not on ARV’s initially, 4 were sent for ARV initiation after the first 
consultation, 1 was sent after treatment, and the status of the remaining 2 patients 
is unknown. 
Risk factors for Anal Carcinoma: 
The following risk factors were included in the data collection proforma; HIV status, 
HPV presence on the histology specimen, female gender, history of sexually 
transmitted infections and genital warts, sexual promiscuity (>10 partners), 
receptive anal intercourse and cigarette smoking.  
It was not possible to do an analysis of the risk factors for anal carcinoma, other 
than HIV status and gender, due to missing data. 
8.1.4 TUMOUR CHARACTERISTICS 
The TNM staging system was used to stage the tumours (appendix 1). 
Prior to starting treatment the median tumour size was 6 cm (range 1-20 cm).  The 
distribution is shown below. 
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Figure 4: Initial tumour size 
In this study, 68% of patients presented with advanced tumours (T3/T4) and 60% 
presented with node positive disease. Fifty-two per cent of the study group had 
both node positive and advanced T-stage disease. 
There was no significant association noted between age and presenting stage, or 
between gender and stage at presentation. 
There was, however a significant association noted between HIV status and 
presenting T-stage. The HIV positive group had a higher proportion of T3 tumours, 
and a lower proportion of T2 tumours, than the HIV negative group. See the graph 
below for the distribution of HIV status and stage at presentation.   
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Figure 5: HIV status 
There was no significant association noted between HIV status and N-stage. 
8.2 TOXICITY  
Toxicity was graded according to the RTOG acute radiation morbidity scoring 
criteria (appendix 4). In this study, the commonest toxicity experienced was skin 
toxicity, in 81% of patients, followed by pain and fatigue in 75% of patients. GIT 
toxicity was experienced by 32% of patients, urinary toxicity in 26% of patients and 
haematological toxicity was noted in 12% of patients.  
Grade 3 skin toxicity was recorded in 19% of patients and grade 4 skin toxicity 
occurred in 42% of patients.  In cases where it was noted in patient files that there 
was skin toxicity present, but there was no recorded grade, ‘yes’ was captured 
during data collection. See figure 6 below for the distribution of grades of skin 
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Figure 6: Skin toxicity 
There was no significant association noted between HIV status and skin toxicity. 
Skin toxicity was the predominant cause for the 33% prevalence of treatment splits 
that occurred.   
Most patients (68%) who required a treatment split, had a split of 5 days or less.  
Forty-seven per cent of the split patients were hospitalised when treatment was 
split, and 32% were not. The remaining 21% had missing data.  The predominant 
cause for the splitting of treatment was skin toxicity. 
8.3 OUTCOMES 
Data regarding treatment related factors which may impact the outcomes, is 
presented below.  
8.3.1 TREATMENT RELATED FACTORS  
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The median delay was 47 days (range 4-432 days). The distribution of the data is 
shown below: 
 
Figure 7: Treatment initiation delay 
After the planning CT scan and field placement were performed, the treatment 
prescriptions were filled out. Six per cent of patients (4 patients) had their 
prescriptions altered from the normal protocol to receive radiation only, due to 
electrolyte and other blood test abnormalities such as a low haemoglobin result. 
The remaining 94% of patients (60 patients) were prescribed both chemotherapy 
and radiotherapy. Of those, 54 were to receive concurrent 5FU days 1-4 and 22-
25, as well as mitomycin c day 1. Four patients were to receive 5FU and cisplatin 
and 1 patient was to be given 5FU only on days1-4 and 22-25 and not mitomycin c 
on day 1. The chemotherapy regimen to be given in 1 patient was not 
documented. The reasons for adjustments made to the standard chemotherapy 
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regimen were low white cell counts, low CD4 counts and in one instance, 
mitomycin c was out of stock. 
Out of the 64 patient’s initially accepted and prescribed for radical treatment, 11% 
(7 patients) did not ultimately begin treatment. The reason for this was not 
recorded in 2 patients. One patient had a low haemoglobin and electrolyte 
abnormalities, was referred back to their local hospital to correct these 
abnormalities, and was not seen again. The remaining four patients demised while 
awaiting treatment initiation.    
Thus 57 patients of the initial 64 went on to start treatment. 
8.3.1.2 TREATMENT 
The median total radiation dose delivered was 56Gy.  See the graph below for the 
distribution of total treatment radiation dose. 
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Figure 8: Total dose 
8.3.1.3 BOOST 
Fifty six per cent of patients received a boost. The commonest boost dose was 
6Gy. 
Seventy-four per cent of patients completed their full course of treatment.  
The reason for not completing the full prescribed course of treatment was not 
documented in 11 out of 15 patients.  
As for the other 4 patients: one patient developed metastases on radical treatment 
and the script was thus altered to a palliative dose. Two patients who were initially 
prescribed a boost were found to have no residual tumour after completion of the 
first two phases of treatment and thus the boost was not given. The remaining 
patient developed an infected perianal ulcer and thus treatment was stopped. 
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8.3.1.4 DURATION OF TREATMENT:  
The median duration of treatment was 44 days (range 0-216 days).  The 
distribution of the data is shown in figure 9 below: 
 
Figure 9: Treatment duration 
8.3.1.5 MISSED DAYS OF TREATMENT: 
During data collection it was noted that there was a high prevalence of patients 
who missed treatment for several days during their scheduled course of radiation. 
The missed days were seldom consecutive. These gaps did not affect the total 
dose of radiation delivered, as the originally prescribed dose and number of 
fractions was completed, but the overall treatment time was affected. These gaps 
were not doctor initiated treatment splits related to toxicity of treatment, as there is 
no documentation in the notes accounting for the gaps. Rather one may assume 
that for some reason, patients were unable to attend treatment on these days.  
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Eighty-one percent of the patients had missing days in treatment.  Within these 46 
patients: 
The median number of missed treatment days was 4 (range 1-49 days).  The 
distribution of the data is shown below in figure 10: 
 
Figure 10: Missed treatment days 
There was a significant association between whether or not days of treatment 
were missed and tumour response at follow up.  All seven patients who had no 
missed days had a complete response. However, the 33 patients who had missed 
treatment days, included patients with stable and progressive disease. See figure 
11 below: 
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Figure 11: Tumour response versus missed treatment days 
8.3.2 TREATMENT RESPONSE  
Response was measured using the RECIST criteria (appendix 5).    
In the 45 evaluable patients who attended follow-up after completing their 
treatment, 42% had a complete response and 36% had a tumour recurrence. 
Partial response was noted in 2% and stable disease in 11%. The response was 
not recorded in the remaining 9% of patients. The median duration to recurrence 
was 303 days. 
The distribution of the outcomes on follow-up is shown in the figure 12 below. 
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Figure 12: Tumour response at follow-up 
8.3.3 FOLLOW-UP DURATION: 
The median follow-up duration was 392 days (91-597 days IQR). This distribution 














































































Tumour response at follow up
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Figure 13: Follow-up durations 
8.3.4 PROGRESSION FREE SURVIVAL  
 
The Kaplan-Meier estimate of progression-free survival is shown below:   
The progression-free survival estimates at 12 and 24 months were 85% and 46%.  
The median progression-free survival time was 19 months. 
See figure 14 below. 
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Figure 14: Progression free survival 
8.3.5 OVERALL SURVIVAL  
No deaths were recorded in those patients that stopped attending follow-up, so it 
was not possible to do an analysis of the overall survival rates. 
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9 DISCUSSION  
This study was a descriptive analysis which aimed to report on various aspects 
relating to chemo-radiotherapy of localised anal cancer. Included were the patient 
and tumour characteristics, treatment toxicities and the treatment outcomes.  
Treatment outcomes are affected by a variety of factors, including patient related 
factors such as performance status and HIV status, tumour related factors such as 
presenting tumour stage and tumour grade, as well as treatment related factors 
such as dose, delays in starting treatment and overall treatment time. These are 
discussed below. 
9.1 PATIENT CHARACTERISTICS  
9.1.1 DEMOGRAPHICS  
This study included data from 64 patients of which 67% were female and 50% 
were HIV positive. The median age of the patients in the study was 48 years. 
The female predominance as well as the age at presentation was consistent with 
the data recorded in the literature.  7,14 
9.1.2 HIV  STATUS  
A review of the literature with regards to age at presentation with anal cancer, 
showed that this variable is affected by HIV status. HIV negative patients 
presented with the disease about two decades later than HIV positive patients. In 
addition, most of the literature showed a female predominance, with the exception 
of regions and eras where HIV was commoner in males, usually related to 
homosexual behaviour patterns.  4,9,14 
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The average age at presentation of the HIV positive patients in this study was 43 
years old, compared to 59 years old for the HIV negative patients.   
Thus the epidemiological findings of this review are consistent with those trials in 
the literature which included HIV positive patients with regards to the female 
predominance and the age at presentation. 
Information regarding other risk factors for anal cancer, including sexual history, 
smoking history and a history of sexually transmitted infections, was lacking in the 
patient files. Thus a conclusion could not be drawn regarding these variables. On 
the other hand, documentation regarding HIV status, CD4 counts and ARV use 
was more comprehensive and this thus enabled an analysis.  
Most of the patients (78%) who were HIV positive were on ARV therapy prior to 
starting treatment, with a median CD4 count of 250 cells/mm3. Those patients who 
were not on ARVs before starting treatment were referred to initiate HAART 
therapy. The fact that the majority of the HIV positive patients included in the study 
were on ARV therapy and had a median CD4 count >200 cells/mm3, may account 
for the reason that the treatment toxicities experienced did not differ from those in 
studies which included HIV negative patients.   
As discussed previously, an outcomes analysis of HIV positive patients with anal 
squamous cell carcinoma by Place et al. reviewed treatment toxicities and 
outcomes in a group of 73 patients between 1980 and 1999. Only those patients 
who presented in 1998- the last year of the trail- were on ARV therapy. The 
authors concluded that patients with anal cancer who were HIV positive and who 
were not on ARVs, obtained little benefit and had significant toxicity from chemo-
radiotherapy. 10 
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In contrast to this, a paper by Fraunholz et al reported that in their series of 21 HIV 
positive patients, all of whom were on ARV therapy, there was acceptable 
treatment related toxicity and favourable treatment outcomes. Chemotherapy and 
radiotherapy could be completed in all 21 patients, with a reduction in 
chemotherapy dose and/or interruption in radiotherapy in 24% of the group (5 
patients). The five year local control rate was 59%.3 
Down modifications of the radiation and chemotherapy doses were not traditionally 
mandated for HIV positive patients at CMJAH, and they tolerated the same 
treatment protocols as immune competent patients. The exception was in cases 
where patients had a CD4 count of less than 200 cells/mm3. In these cases, 
chemotherapy was either omitted or altered. The alteration made was either to 
omit mitomycin c and use only 5FU, or to use cisplatin as a substitute for the 
mitomycin c. 
In this study the HIV positive patients presented with later T stage tumours then 
the HIV negative patients.    
There was however no significant association between HIV status and a 
requirement to split treatment, missed days of treatment or completion of the 
course of chemo-radiation in this study. 
There was also no significant association between HIV status and tumour 
recurrence. 
9.2  TOXICITY 
The commonest adverse effect noted was skin toxicity. This occurred in 81% of 
patients and the majority had severe grade 3 and 4 reactions. The next 
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commonest toxicities were fatigue and pain, which occurred in 75% of patients. 
GIT toxicity occurred in 32% of patients, and urinary and haematological toxicity 
were less common, occurring in 26% and 12% of patients respectively. 
The distribution of toxicities noted in this study differs somewhat from that in the 
literature. Skin toxicity or dermatitis was also the commonest adverse event noted 
in the literature review14,15, but in this study the next most prevalent adverse 
events noted were fatigue and pain, with GIT toxicity and haematological toxicity 
being less common.     
The reason for the difference may be variations in field borders used in different 
centres, as some may use a higher superior field border and include more bowel 
in the high dose region.  
A possible reason for the ‘lesser occurrence’ of haematological toxicity in this 
study compared to the literature may be differing institutional practices for 
monitoring of full bloods counts while patients are on treatment. At CMJAH, blood 
results are checked prior to administering of chemotherapy, but not always on a 
weekly basis thereafter. This may result in lower detection rates of haematological 
toxicity. 
HIV positive patients did not experience significantly worse treatment toxicities 
than HIV negative patients, nor did they require an increased number of treatment 
splits. They had equal rates of treatment completion when compared to HIV 
negative patients. 
Thus in conclusion the distribution of treatment toxicities noted in this study 
differed somewhat from the that reported in the literature with similar prevalence of 
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skin toxicity but less common haematological and GIT toxicity rates, possibly due 
to variations in field borders and blood count monitoring rates. HIV positive 
patients had similar toxicity profiles and treatment tolerability to HIV negative 
patients.         
9.3 OUTCOMES 
The group of patients who completed their treatment and attended follow-up 
comprised 45 evaluable patients. 
9.3.1 TREATMENT OUTCOMES    
The median duration of follow-up was 392 days. 
Follow-up of patients was done by clinical assessment with a history and an 
examination. It was not the departmental policy to follow-up patients by performing 
routine biopsy. Thus recurrence was diagnosed clinically, and once assessed as 
such- patients were then worked up and referred for biopsy.  
At the last recorded follow-up visit, of the 45 evaluable patients 38% had recurrent 
disease and 51% did not have a recurrence. There was missing data regarding the 
outcome in the remaining 11% of patients. The Kaplan-Meier progression free 
survival rates were 85% at 12 months and 46% at 24 months. The median 
progression free survival time was 19 months.      
Lim et al did a systematic review of chemotherapy/radiotherapy trials in anal 
cancer. Some of the trials included in their review were ACT I and II, ACCORD-03, 
EORTC 22861, RTOG-8704 and RTOG-9811. The authors concluded that 
patients with T3/T4 lesions had poor outcomes, with a 3 year disease free survival 
of 40-68%.17 
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A trial by Gerard et al conducted in France, examined the long term results in a 
group of 95 patients with anal carcinoma, treated with radiation and concurrent 
fluorouracil and cisplatin. Sixty-three per cent of the patients had advanced 
disease with tumours of >4cm in diameter. Only 19% of their patient group with 
tumours <4cm in size had no metastatic lymph node involvement. None of the 
study participants was HIV positive.9  
With regards to the outcomes, in the trial by Gerard et al, local recurrence was 
noted in 14 patients (15 % of the study population), 11 recurrences were in the 
anal canal, 1 was in the perirectal wall above the anus and 2 were in the lateral 
pelvis. The median time to recurrence was 12 months after completion of 
treatment. The loco-regional control rate was initially 80% but with successful 
salvage surgery of 13 patients after relapse, the ultimate loco-regional control rate 
was 93%.9 
In contrast to the trial by Gerard et al, the outcomes of this study more closely 
reflect those noted in the paper by Lim et al.17 Of course the outcomes and local 
control rates would need to be compared over a similar time frame, as the current 
outcome data from this study are based on an average follow-up of approximately 
13 months. Unfortunately the patient population in our setting differs from those in 
a first world environment and access to health care is a challenge.  
9.3.2 TREATMENT RELATED FACTORS  
In addition to the stage at presentation, other factors that affect the outcomes 
include radiotherapy fields and doses, chemotherapy use, splits in treatment and 
delays in starting and completing treatment. 
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In a review of the literature regarding radio-chemotherapy in anal cancer, the 
treatment protocol at CMJAH is comparable to other centres. One notable 
difference is that 5-fluorouracil is administered as a bolus over 4 days at CMJAH, 
instead of being given as an infusion, as in the trials by Chapet et al, and Gerard 
et al. 8,9 
In this paper it was noted that there was a median delay of 47 days to initiation of 
treatment and a median treatment duration of 44 days. Eighty-one per cent of 
patients had unplanned gaps in the course of their treatment. In addition 33% of 
patients needed a split in treatment due to toxicity. These factors contribute to a 
delay in starting radiotherapy as well as an increase in the overall treatment time.     
There is literature to suggest that the potential doubling time (Tpot) of anal cancer 
is 4 days.2 The potential doubling time is defined as the time necessary to double 
the number of proliferating tumour cells in the absence of spontaneous cell loss. 
Thus a delay in initiating therapy, as well as prolonged overall treatment times 
would lead to upstaging of the tumour and worse treatment outcomes.  
A systematic review entitled “does delay in starting treatment affect outcome of 
radiotherapy” by Huang et al reviewed 47 studies which included 15 782 patients 
with a variety of malignancy types, the commonest being breast and head and 
neck cancer. The authors found that there was an association between an 
increased local recurrence rate in these cancers and a delay in initiating 
radiotherapy. One may extrapolate from this data that a delay in starting treatment 
in anal cancer is also associated with reduced local control rates.18 
On statistical analysis of the data from this trial, there was no significant 
association between the delay in starting treatment, or a planned split in treatment 
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and adverse outcomes. There was also no increase in local recurrence in those 
patients who did not receive a boost, compared to those who did. 
There was no significant association noted between T and N stage and outcomes. 
There was also no significant association noted between recurrence and HIV 
status, age and gender. 
There was however a significant association between adverse outcomes and 
missed treatment days. There was a complete response in all patients who did not 
miss days of treatment. However, the patients who did have unscheduled gaps in 
treatment included those with stable disease and disease progression and had a 
complete response rate of less than 40%. 
Thus the most significant factor related to recurrence in this study, was 
unscheduled gaps during treatment. 
9.4 STRENGTHS AND LIMITATIONS  
A strength of this study is that multiple data variables and outcomes were collected 
and analysed. Although not complete, the data in the patient files provided a 
strong base for a hypothesis for further research questions related to anal cancer 
treatment at CMJAH.  
Another positive aspect of the study, is that the research was inexpensive to 
conduct as it relied upon data already present in departmental files.   
One of the limitations of this study lies in the fact that it was conducted 
retrospectively. This led to a limitation of the available data in the files, most 
notably the lack of charting of risk factors for anal carcinoma and paucity of 
information about the grade of treatment related toxicities experienced.  
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A further limitation of the study was the poor follow-up of patients during and after 
radiotherapy. This led to an inability to measure overall survival outcomes. It may 
also have resulted in an over-estimation of the progression free survival rates as 
progression may have occurred quite some time before it was documented.  
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10 CONCLUSION 
Anal carcinoma causes significant morbidity to patients and is one of the few 
cancer types that relies on treatment from oncologic services primarily, rather than 
surgical services. Anal carcinoma is a tumour in which it is comparatively easy to 
assess treatment response and outcome in, as it is accessible to clinical 
examination. Measuring local response does not require imaging or blood tests. 
Thus, in our resource constrained environment, there are fewer barriers to 
ensuring sound follow-up, compared to other carcinomas, such as lung or stomach 
cancer.  
The demographics, treatment toxicities and outcomes in this study largely 
paralleled those in the literature for centres with a similar patient HIV burden and 
presenting tumour stage. 
Better documentation and patient follow-up is needed to get a clearer picture of 
the acute tumour response to therapy and the long term treatment outcomes. 
Better monitoring of patient attendance during treatment is also imperative as 
unplanned gaps in chemo-radiation were correlated with recurrence in this study. 
Further studies may look at the quality of life of these patients with regards to 
sphincter preservation rate, sexual function, and long term urinary and bowel 
function post pelvic radiotherapy.  
Another area of future interest is the effect on the incidence of anal carcinoma in 
women, related to the national rollout of the HPV vaccination. The programme was 
initiated in 2014, with girls from age 9 and onwards being vaccinated. The main 
aim was to reduce the incidence of cervical cancer, but since HPV is also a risk 
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factor for anal cancer, reduced numbers of this type of malignancy may be a spin-
off benefit of wide-spread HPV vaccination.  
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11 APPENDICES 
11.1 APPENDIX 1:  AJCC  7TH EDITION TMN  STAGING OF ANAL CARCINOMA 
T-Staging 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ (i.e., Bowen disease, high-grade squamous intraepithelial 
lesion, and anal intraepithelial neoplasia II–III.) 
T1 Tumour ≤2 cm in greatest dimension. 
T2 Tumour >2 cm but ≤5 cm in greatest dimension. 
T3 Tumour >5 cm in greatest dimension. 
T4 Tumour of any size invades adjacent organ(s), e.g. vagina, urethra, and 
bladder. 
N-staging 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastases in perirectal lymph node(s). 
N2 Metastases in unilateral internal iliac and/or inguinal lymph node(s). 
N3 Metastases in perirectal and inguinal lymph nodes and/or bilateral internal     
iliac and/or inguinal lymph nodes. 
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M-staging 
M0 No distant metastasis. 
M1 Distant metastasis. 
11.2 APPENDIX 2:  PROFORMA FOR DATA COLLECTION 
Category 1: Patient Demographics 















4.  Patient gender: 
 
 Male Female 
A.  
  





6.  Degree of differentiation on histology: 
 
 Well Moderate Poor Unknown 
B.  
  





8.  HPV on histology: 
 
 Present Absent Unknown 
c.  
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11.  Initial performance status: 
 
 EGOC0 ECOG1 ECOG2 ECOG3 ECOG4 
D.  
  
12.  HIV status: 
 
 Positive Negative Unknown 
 
  
13.  If HIV positive, what is CD4 count on presentation: 
 
  Unknown 
 
  
14.  If patient is HIV positive, are they on ARV’s prior to starting radiation: 
 
 Yes (Date Initiated) No Unknown 
 
  
15.  If not on ARVs at presentation, was the patient sent to initiate ARV 
treatment: 
 
 Yes No Unknown 
 
  
16.  Other risk factors for anal carcinoma (Check all which apply):  
 
 □ History of STI 
Syphilis Herpes Gonorrhoea Chlamydia 
□ History of Anal Warts 
□ Sexual Promiscuity (>10 sexual partners) 
□ Receptive Anal Intercourse 
□ Smoking 
Current Previous Unknown 
 
  
17.   If positive smoking history, Number of pack years: 
 
 <  0 =>10 Unknown 
 
  
Category 2: Treatment 
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18.  Prescribed Treatment: 
 
Chemo-Radiation Radiotherapy Only 
 
  
19.  If chemotherapy given, which drugs given: 
 
5FU D1-4 and 22-25 and 
MMC D1 
5FU D1-4 and 22-25, and Cisplatin D1 
 
  
20.  If chemotherapy omitted/altered, cause for this: 
 
Low CD4 count Poor Performance Status Age Unknown 
 
  










23.  If the patient did not get treatment although it was planned, cause for this: 
 








24.  Was there a colostomy inserted: 
 
Yes No Unknown 
 
  
25.  If a colostomy was inserted, when was this done: 
 
Prior to starting 
treatment 




















29.  If full course of prescribed RT was not completed, what dose was 
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33.  If treatment was split, was patient admitted to hospital during the split: 
 
Yes No Unknown 
 
  





























































Category 3: Tumour Response 
36.  Tumour size in CM: 
 




(              ,Unknown) 




(              ,Unknown) 
If boosted, size of 
tumour on 
completion of boost: 
 
(              ,Unknown) 
 
  
37.  Response at Completion of all Planned Treatment: 
 

























Category 4: Treatment Toxicities 
39.  On treatment complications: 
 






































Fatigue Yes No Unknown 
 






Category 5: Outcomes 
40.  If patient did follow-up after treatment completion, and there was 

























43.  On last date seen, what was the tumour response: 
 












44.  If there was persistent disease/progression/recurrence, what was done 













11.3 APPENDIX 3:  EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS 
Grade 0: Fully active, able to carry on all pre-disease performance without 
restriction 
Grade 1: Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, office work 
Grade 2: Ambulatory and capable of all self-care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
Grade 3: Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours 
Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair 
Grade 5: Dead 
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11.4 APPENDIX 4:  RTOG  ACUTE RADIATION MORBIDITY SCORING CRITERIA 











Tender or bright 




















Frequency of urination or 
nocturia which is less 
frequent than every 
hour. Dysuria, urgency, 
bladder spasm requiring 
local anaesthetic (e.g., 
Pyridium) 
Frequency with urgency 
and nocturia hourly or 
more frequently/ 
dysuria, pelvis pain or 
bladder spasm requiring 
regular, frequent 
narcotic/gross 





not secondary to clot 









change in quality of 
Diarrhoea requiring 
parasympatholytic drugs 
(e.g., Lomotil)/ mucous 
Diarrhoea requiring 
parenteral support/ 
severe mucous or blood 
Acute or subacute 
obstruction, fistula or 
perforation; GI 
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pads/ rectal or 
















WBC (X 1000) 
>=4.0 3.0 - <4.0 2.0 - <3.0 1.0 - <2.0 <1.0 
PLATELETS (X 
1000) 
>=100 75 - <100 50 - <75 25 - <50 <25 or spontaneous 
bleeding 
NEUTROPHILS >=1.9 1.5 - <1.9 1.0 - <1.5 0.5 - <1.0 <0.5 or sepsis 
HEMOGLOBIN 
(GM %) 
>11 11-9.5 <9.5 - 7.5 <7.5 - 5.0 ------- 
HEMATOCRIT (%) 
>=32 28 - <32 <28 Packed cell transfusion 
required 
------- 
GUIDELINES: The acute morbidity criteria are used to score/grade toxicity from radiation therapy. The criteria are relevant from day 
1, the commencement of therapy, through day 90. There-after, the EORTC/RTOG Criteria of Late Effects are to be utilized. 
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The evaluator must attempt to discriminate between disease- and treatment-related signs and symptoms. 
An accurate baseline evaluation prior to commencement of therapy is necessary. 
All toxicities Grade 3, 4 or 5* must be verified by the Principal Investigator. 
*Any toxicity which caused death is graded 5. 
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11.5 APPENDIX 5:  REVISED RECIST  GUIDELINES (  VERSION 1.1) 
Evaluation of target lesions 
1) Complete Response (CR): Disappearance of all target lesions. Any 
pathological lymph nodes (whether target or non-target) must have a 
reduction in the short axis to <10mm. 
2) Partial Response (PR): At least a 30% decrease in the sum of diameter of 
target lesions, taking as reference the baseline sum diameters. 
3) Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum 
diameters while on the study. 
4) Progressive Disease (PD): At least a 20% increase in the sum of diameters 
of target lesions, taking as reference the smallest sum on study (this 
includes the baseline sum if that is the smallest on study). In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5mm (note the appearance of one or more new lesions 
is also considered progression of disease). 
11.6  APPENDIX 6:  ETHICS CLEARANCE CERTIFICATE 
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11.7  APPENDIX 7:  ETHICS CHANGE OF SUPERVISOR  
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